Table 1. Median (min‐max) concentrations of angiotensin peptides produced from homogenized tissues incubated with and without various enzyme inhibitors.
| AngII formation (pg/μg protein)/h Median (min‐max) | Ang1‐7 formation (pg/μg protein)/h Median (min‐max) | Ang1‐7 formation (pg/μg protein)/h Median (min‐max) | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | Chymostatin | Chymostatin and lisinopril | Control | ZPP | ZPP and MLN‐4760 | Control | LBQ‐657 | |
| LVPW |
24.5 (14.8–46.9) |
24.7 (13.8–43.5) |
all below LLOQ |
613 (277–935) |
178 (140–340) |
all below LLOQ |
2004 (1831–2334) |
1824 (1760–2238) |
| IVS |
28 (17.9–54.9) |
22.5 (15.1–54.0) |
all below LLOQ |
647 (283–919) |
155 (118–355) |
all below LLOQ |
2232 (1746–2793) |
2005 (1640–2733) |
| Kidney |
557.2 (114.7–1485.4) |
553.9 (110.5–1418.3) |
all below LLOQ |
24297 (14573–29700) |
21960 (12213–26524) |
889.5 (508–1372) |
3862 (3221–4132) |
1964.5 (1810–2641) |
Ang1‐7, Angiotensin 1‐7; AngII, Angiotensin II; IVS, interventricular septum; LLOQ, lower limit of quantitation (<5 [pg/μg protein]/h); LVPW, left ventricular posterior wall.